Event > Conference >
SLAS2023
The Society for Laboratory Automation and Screening (SLAS) is an international professional society of academic, industry and government life sciences researchers coupled with the developers and providers of laboratory automation technology.
Head to our exhibition stand – #1451
We look forward to meeting you to showcase our new product launch and more widely discuss how our PhysioMimix™ range of organ-on-a-chip (OOC) products and services can help to improve the predictivity of your workflows.
Talk to our team to be introduced to our human-relevant single- and multi-organ in vitro models and learn more about their proven track record for delivering clinically translatable results.
Our dedicated team of creative problem solvers will be available to share our decade of OOC expertise with you during the exhibition, poster sessions and at our exhibitor tutorial.
The Next Generation of PhysioMimix…
You’ll have to visit our exhibition stand or seminar to learn more!
Symposiums/Tutorials
Is your in vitro toolbox as cutting-edge as your portfolio of drug modalities?
Next-generation therapeutics have become a popular way to improve drug delivery, target what was previously considered “undruggable”, and bring novel medicines to patients swiftly. A recent McKinsey report cites that new drug modalities represent around 21% of pipelines – the fastest growth ever seen in the sector.
In this modern era of drug discovery, has your preclinical assay toolbox kept pace with the differing needs of new modalities versus small molecules? For small molecules, traditional in vitro assays are complemented by in vivo animal models. But, for drugs with human-specific modes of action, there are few non-clinical in vivo models available. As such, safety and efficacy testing this new wave of therapeutics represent a significant workflow challenge.
Organ-on-a-chip (OOC), otherwise known as microphysiological systems (MPS), offer a path forward, delivering clinically translatable data that be used to predict the efficacy, drug disposition and safety of drugs – irrespective of modality.
With primary human cells at their core, these complex multicellular in vitro models recapitulate the physiology and function of human organs, including key immune aspects. They can be linked to simulate processes such as drug absorption and metabolism or to understand interactions between organs, such as inflammation, which drive disease and cause unexpected toxicities.
Join our seminar and networking lunch to learn:
- about the unique insights that OOC/MPS deliver when part of a modern-day toolbox
- how to predict the behavior of therapeutics (of any modality) in human more accurately
- about the next generation PhysioMimix™ OOC, designed to better meet the needs of industry – launching at SLAS 2023.
Date: Monday 27th February
Time: 12:00 PM – 1:30 PM
Room: 16B
Presentation from:
Dr Paul Brooks – CEO
Dr Audrey Dubourg – Product Manager
Dr Anthony Berger – Field Application Scientist
Lunch Provided
Our Team at SLAS2023
Paul
Dr Paul Brooks is CEO at CN Bio, having joined in 2022. He has over 25 years of experience in building businesses and leading high-performance research, product, marketing, and sales teams to develop and commercialize new biotechnology technologies globally for drug discovery, bioproduction and diagnostics.
Dr Brooks has held senior leadership positions in the USA and the UK, including Head of Business Operations and Managing Director of Horizon Discovery Ltd; Chief Commercial Officer and Executive Board member of Oxford Genetics Ltd; Head of Discovery Research Services at MilliporeSigma (Merck KGaA); and Global Marketing Manager at Sigma-Aldrich Corp. Dr Brooks has a BSc in Biochemistry from the University of Wales, a PhD in Molecular Biology from the University of Manchester Institute of Science and Technology (UMIST), and an MBA from the University of Nottingham Business School.
Audrey
Dr Audrey Dubourg is CN Bio’s Product Manager for the PhysioMimix™ OOC range of microphysiological systems. Prior to joining CN Bio, she worked as a postdoctoral scholar at the University of California – Los Angeles (UCLA), in the US, in the Microbiology, Immunology and Molecular Genetics department. She completed an MSc in microbiology at the University of Montpellier II, followed by a PhD in microbiology/parasitology at the University of East Anglia. Audrey has extensive experience in the disciplines of molecular biology and 3D mammalian cell culture. Since joining CN Bio, she has been actively involved in promoting the benefits of incorporating organ-on-a-chip technology into drug discovery and development workflows.
Brian
Dr Brian Manning – Global Head of Sales, is a PhD-qualified pharmacologist, Brian trained in Ireland, France, and the USA before spending 10 years in Big Pharma drug discovery, where he also completed his MBA. He joined CN Bio Innovations in 2020 and prior to that, had a successful career in delivering rapid sales growth for cutting-edge cell culture companies in the UK and US, specializing in organ-on-chip and spheroid cultures over the last 6 years. Currently based in New Jersey, USA, Dr. Manning holds a PhD from the National University of Ireland an MBA from Rensselaer Polytechnic Institute.
James
James Ferritto is the Western US Sales Manager for CN Bio, based out of the Bay Area. In his role, James supports researchers looking to bring more predictive data to their drug development process. He has a track record of helping scientists identify & implement new technologies to improve research outcomes. James is excited by the PhysioMimix™ Organ-on-Chip platform since he has experienced how it enables more relevant decision-making in preclinical stages. James holds a BS from Boston University (US).
Anthony
Dr Anthony Berger is CN Bio’s US-based Field Application Scientist, providing support for the PhysioMimix™ Organ-on-Chip benchtop platform. Anthony has an extensive research background in 3D cell culture, biomaterials, and microfluidics, focusing on how the microenvironment influences cellular decision-making. He is a proponent of complex 3D in vitro models and desires to decrease the barrier to entry of these technologies. Anthony received his BS from Indiana University (US), PhD from the University of Wisconsin (US), and completed a postdoctoral fellowship at Temple University (US).